Intellia Therapeutics (NASDAQ:NTLA) Receives “Overweight” Rating from Cantor Fitzgerald

Intellia Therapeutics (NASDAQ:NTLAGet Free Report)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $65.00 price target on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 161.89% from the company’s current price.

A number of other research firms have also weighed in on NTLA. BMO Capital Markets upped their price objective on shares of Intellia Therapeutics from $62.00 to $70.00 and gave the stock an “outperform” rating in a research note on Friday, May 10th. Citigroup lowered their price objective on shares of Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Friday, May 10th. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research note on Friday, May 10th. Canaccord Genuity Group upped their price objective on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. Finally, Wedbush reaffirmed a “neutral” rating and issued a $29.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday, April 23rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Intellia Therapeutics has an average rating of “Moderate Buy” and an average price target of $64.75.

Read Our Latest Stock Analysis on NTLA

Intellia Therapeutics Stock Performance

NTLA stock traded down $0.35 during mid-day trading on Tuesday, reaching $24.82. 328,911 shares of the stock traded hands, compared to its average volume of 1,506,668. Intellia Therapeutics has a one year low of $19.37 and a one year high of $46.50. The stock has a market capitalization of $2.39 billion, a PE ratio of -4.64 and a beta of 1.84. The business has a 50-day moving average price of $23.64 and a two-hundred day moving average price of $26.64.

Intellia Therapeutics (NASDAQ:NTLAGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($1.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.35) by $0.29. The business had revenue of $28.94 million for the quarter, compared to analysts’ expectations of $15.60 million. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 45.35%. On average, equities analysts expect that Intellia Therapeutics will post -4.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Intellia Therapeutics

Hedge funds have recently modified their holdings of the stock. Avidity Partners Management LP increased its holdings in shares of Intellia Therapeutics by 18.0% during the fourth quarter. Avidity Partners Management LP now owns 447,434 shares of the company’s stock valued at $13,642,000 after acquiring an additional 68,334 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Intellia Therapeutics by 2.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 700,228 shares of the company’s stock valued at $21,350,000 after acquiring an additional 18,987 shares in the last quarter. ARK Investment Management LLC increased its holdings in shares of Intellia Therapeutics by 14.7% during the fourth quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock valued at $347,966,000 after acquiring an additional 1,463,820 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Intellia Therapeutics by 5.9% during the third quarter. American Century Companies Inc. now owns 267,213 shares of the company’s stock valued at $8,449,000 after acquiring an additional 14,863 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. increased its holdings in shares of Intellia Therapeutics by 13.3% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 36,225 shares of the company’s stock valued at $1,104,000 after acquiring an additional 4,255 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

(Get Free Report)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

See Also

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.